Key facts
- This page summarizes Jeffrey W. Jacobs's Form 4 filing for ARDELYX, INC. (ARDX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 24 Nov 2021, 15:06.
Jeffrey W. Jacobs - 22 Nov 2021 Form 4 Insider Report for ARDELYX, INC. (ARDX)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- ARDX
- Reported as of
- 22 Nov 2021
- Net transaction value
- -$5,629
- SEC form
- 4
- Accepted by SEC
- 24 Nov 2021, 15:06:29 UTC
- Prior SEC filing
- 16 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Grammer, Attorney-in-Fact for Jeffrey W. Jacobs
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey W. Jacobs filed Form 4 for ARDELYX, INC. (ARDX) on 24 Nov 2021.
Change
- Previous filing in this sequence was filed on 16 Nov 2021.
- Current net transaction value: -$5,629.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARDX
transaction
Common Stock
Sale
- Transaction value
- $4,882
- Shares
- -5,000
- Change %
- -4%
- Price
- $0.9763*
- Shares after
- 120,237
- Date
- 22 Nov 2021
- Ownership
- Direct
- Footnotes
- F1, F2
ARDX
transaction
Common Stock
Sale
- Transaction value
- $748
- Shares
- -754
- Change %
- -0.63%
- Price
- $0.9919
- Shares after
- 119,483
- Date
- 22 Nov 2021
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 29, 2021.
Footnote F2
This transaction was executed in multiple trades in prices ranging from $0.96 to $0.992, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F3
Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.